ConductScience.org, home

Comparison · NCT01075178-6519d40d

Palivizumab-treated Subjects (CASES) vs Non-palivizumab-treated Subjects (CONTROLS): Comparison Between CASES and CONTROLS of the Occurrence of Specific Clinical Outcomes of Serious Infection.

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

2 sourcestrial-comparisons-2026-03-23-0.1.0

Download JSON
Cite this record

ConductScience Library. Palivizumab-treated Subjects (CASES) vs Non-palivizumab-treated Subjects (CONTROLS): Comparison Between CASES and CONTROLS of the Occurrence of Specific Clinical Outcomes of Serious Infection. Trial comparisons, record NCT01075178-6519d40d. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT01075178-6519d40d

On this page

Measures6

Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.

MeasureValue95% interval, lower95% interval, upperMethodNote
Risk in group 10.2780.2520.307wilson
Risk in group 20.3260.2980.356wilson
Risk difference, group 1 minus group 2-0.0476-0.0874-0.0075newcombe hybrid score
Risk ratio, group 1 over group 20.8540.7480.976log
Odds ratio, group 1 over group 20.7980.6590.965log
Number needed to treat, for one fewer participant with the outcome on Palivizumab-treated Subjects (CASES) than on Non-palivizumab-treated Subjects (CONTROLS)2111.4133from the risk difference interval

Groups2

Neither group, or both, names a comparator, so the groups keep ClinicalTrials.gov's order.

GroupTitleDescriptionWith the outcomeAnalysedClinicalTrials.gov code
Group 1Palivizumab-treated Subjects (CASES)HSCHD infants, \<2 yrs old at first dose of palivizumab2811,009OG000
Group 2Non-palivizumab-treated Subjects (CONTROLS)HSCHD infants, \<2 yrs old that did not receive palivizumab3291,009OG001

Outcome

Type
PRIMARY
Title
Comparison Between CASES and CONTROLS of the Occurrence of Specific Clinical Outcomes of Serious Infection.
Description
The number of subjects who experienced at least 1 event of infection meeting any of the criteria for a serious adverse event
Time frame
8-month chart review period in CASES and CONTROLS
Population
The population analyzed included the full analysis set.

Source ClinicalTrials.gov

Trial

Title
Retrospective Palivizumab Study in Children With Hemodynamically Significant Congenital Heart Disease
NCT number
NCT01075178
Phases
Conditions
Severe Respiratory Syncytial Virus Infection
Interventions
Lead sponsor
Abbott
Results first posted
2011-02-24

Source ClinicalTrials.gov

Source

Release
trial-comparisons-2026-03-23-0.1.0
Release manifest SHA-256
f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
AACT copy
2026-03-23
Tables read
outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet

Source ClinicalTrials.gov

Sources 2

  • ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
  • ClinicalTrials.govNo license stated
Each source's terms
  • ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
  • ClinicalTrials.govnone stated

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.

For software

Read this comparison from software.

The record is JSON. No key.

GET https://conductscience.org/api/comparisons/v1/NCT01075178-6519d40d